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1. Introduction 
Muscarinic activation of Airway smooth muscle (ASM) is of major importance to the 
physiological and patho-physiological actions of acetylcholine, which induces 
bronchoconstriction, airway smooth muscle thickening, and the modulation of cytokine and 
chemokine production by these cells as described in [1]. The parasympathetic nervous 
system is the dominant neuronal pathway in the control of airway smooth muscle tone. 
Stimulation of cholinergic nerves causes bronchoconstriction, and mucus secretion as in [2]. 
The human airways are innervated via efferent and afferent autonomic nerves, which regulate 
many aspects of airway function. It has been suggested that neural control of the airways may 
be abnormal in asthmatic patients, and that neurogenic mechanisms may contribute to the 
pathogenesis and pathophysiology of asthma. Although abnormalities of the cholinergic 
innervation have been suggested in asthma, thus far the evidence for cholinergic dysfunction 
in asthmatic subjects is not convincing as mentioned in references  [1,2].  
Acetylcholine (Ach) is the predominant parasympathetic neurotransmitter, acting as an 
autocrine or paracrine hormone in the airways and its role in the regulation of 
bronchomotor tone and mucus secretion from airway submucosal glands in the respiratory 
tract is well established as described in [2]. More recent findings suggest that acetylcholine 
regulates additional functions in the respiratory tract, may promoting airway inflammation 
and remodelling, including airway smooth muscle thickening in inflammatory lung diseases 
as reported in references [3-5]. Another source of ACh is the non-neuronal cells and tissues, 
particularly inflammatory cells and the airway epithelium as described in references [6-8].  
Collectively, these findings indicate that acetylcholine, derived from the vagal nerve and 
from non-neuronal origins such as the airway epithelium, may induce cell responses 
associated with airway wall remodelling and trigger proinflammatory Cytokines as IL-6 and 
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IL-8 release in [9] by structural cells of the airways, including the airway smooth muscle 
itself. In addition, muscarinic receptors regulate proliferative and proinflammatory 
functions of the airway smooth muscle as mentioned in references [9,10]. 
Acetylcholine acting on muscarinic receptors (mAChRs) anchored at the airway smooth 
muscle sarcolemma are involved in the generation of a number of signal transducing 
cascades allowing the activation of the smooth muscle machinery as described in [11]. 
Airway smooth muscle muscarinic activation is mediated through mAChRs, which are 
members of the so called G protein-coupled receptors (GPCR) family, which are cell surface 
receptors, that activate intracellular responses by coupling G proteins as described in [12] to 
specific effectors in [13]. Molecular cloning studies have revealed the existence of five 
mammalian subtypes of muscarinic receptors (m1-m5) as described in [14]. In trachea, 
smooth muscle expresses mRNAs coding for both m2 and m3 receptors as reported in [15]. 
Airways smooth muscarinic receptors have been identified as a mixed population of M2 and 
M3 subtypes roughly in a 4:1 ratio using pharmacological ligand binding studies in [16,17] 
being the M2 subtype, the most abundant muscarinic receptor in tracheal plasma 
membranes as reported in references [16,18,19]. In addition, a muscarinic antagonist 
heterogeneity associated with the M3AchR subtype present in plasma membrane fractions 
from tracheal smooth muscle has been described in [20]. 
It has been claimed that M3AChR represents a primary target of acetylcholine in the air-
ways, involved in the regulation of bronchoconstriction as stated in references [17,18,21,22]. 
Classically, M3AChRs in ASM are coupled to phospholipase C (PLC)/protein kinase C (PKC) 
pathway via pertussis toxin (PTX)-insensitive G proteins of the Gq/11 family. The contractile 
response evoked by M3AChRs stimulation is attributed to the formation of inositol trisphos-
phate (IP3), the subsequent release of Ca2+ from intracellular stores, the additional influx of 
extracellular calcium, and the Ca2+-sensitizing effect of PKC as mentioned in [21,23,24]. 
On the other hand, the stimulation of M2 muscarinic receptors (M2AChRs) in ASM inhibits 
adenylyl cyclase via activation of PTX-sensitive G proteins of the Gi/o family in [25,26] and 
therefore M2AChRs are thought to counteract relaxation as reported in [27]. Experimental 
evidence has been provided that M2AChRs participate directly in ASM contraction but the 
molecular mechanisms by which the M2AChRs in ASM induce contraction is, still unknown.   
Recently, it has been shown that M2AChRs stimulate Gi/o proteins to released βγ dimer, 
which inhibit the Large Conductance Ca2+-activated K+ Channel Activity (BK channels) as 
described in [28]. The inhibition of BK channel activity favors contraction of ASM and these 
BK channels are opposed to the M2AChR-mediated depolarization and activation of calcium 
channels by restricting excitation–contraction coupling to more negative voltage ranges as 
mentioned in [29]. 
In addition, the influence of M2AChRs to modulate the relaxant effects of atrial natriuretic 
peptide (ANP) has been reported. Thus, the stimulation of M2AChRs suppresses ANP-
induced activation of particulate guanylyl cyclase via a PTX-sensitive G protein as reported 
in [30]. 
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More recently, we showed that muscarinic agonists, via M2AChR induced a massive and 
selective α1β1-NOsGC migration from cytoplasm to plasma membranes in a dose-
dependent manner. Such migration was blocked by PTX, suggesting the involvement of 
Go/Gi proteins in [31]. 
Some of the signal cascades activated by mAChRs at TSM are linked to the generation of 
second messengers such as cyclic nucleotides: cAMP and cGMP as described in reference 
[32].  In this review, we address the cGMP generation as a product of the muscarinic 
activation of ASM. It is well known that in mammalian cells, cGMP is produced by the 
action of two distinctive guanylyl cyclases, named the NO-sensitive soluble 
guanylylcyclases (NO-sGC) as reported in [33] and the single membrane-spanning guanylyl 
cyclases as published in references [33-35]. 
2. Body: Cyclic GMP signals during muscarinic activation 
The muscarinic activation of tracheal smooth muscle (TSM) fragments associated with 
smooth muscle contraction, involves the generation of two cGMP signals, at 20-s and 60-s as 
described in reference [36] and a kinetic behavior is shown in Figure 1. 
 
Effect of ODQ on the time course of cGMP signals induced by agonist muscarinic carbachol (1x10-5 M) in TSM. 
Tracheal smooth muscle strips were pre-incubated for 30 min with ODQ (1H-[1, 2,4 ] Oxadiazolo[4,3-a]quinoxalin-1-
one) (■) (100 nM) selective inhibitor of NO-sGC, following the Procedure 2 as described in reference 36. Control 
experiments (□) without drug were run simultaneously under the same conditions. Each value is the mean ± SE of 4 
different tracheas and the cGMP determinations were carried out by triplicate as described in reference [36]. 
Figure 1. Time course of muscarinic agonist action on cGMP levels from TSM in the presence of ODQ. 
Taken from reference [36].   
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Interestingly, the 20-s signal is linked to the onset and the 60s signal is related to the plateau 
of the smooth muscle contraction as described in [36]. The 20-s signal is associated with the 
activity of a Soluble guanylyl cyclases, which are nitric oxide stimulated guanylyl cyclase 
(NO-sGC),  which are described in [33] and the second, the 60-s signal, is linked to 
membrane-bound natriuretic peptide receptor guanylyl cyclase (NPR-GC) in references [33-
35], which has been previously characterized at TSM in [37,38].  
The details of the activation of an NO-sGC, generating the early 20-s cGMP signal, presents 
in the plasma membrane of BTSM, has been previously established in reference [31].  
Soluble guanylyl cyclases are nitric oxide stimulated guanylyl cyclase (NO-sGC) due to the 
fact that the primary and best-studied endogenous activator is nitric oxide (NO).  NO-sGC is 
a heterodimeric hemoprotein formed by two different subunits, α- and β-subunits, which 
exist in four types (α1, α2, β1, and β2), each the product of a separate gene as described in 
[39,40]. Structurally, each subunit consists of N-terminal H-NOX domain, a central domain 
related to the dimerization, and a C-terminal consensus nucleotide catalytic cyclase domain 
as described in [41,42]. For the formation of a catalytically active enzyme, both α- and β-
subunits are required as reported in [43]. Although the α1β1 isoform is ubiquitous, the α2β1 
isoform is less broadly distributed described in [39-43]. 
The best-characterized heterodimers are the α1/β1 and the α2/β1 isoforms as mentioned in 
[44] being the first ones, relevant in our studies as in [31]. At molecular level, His-105 at the 
amino terminus of the β1 subunit of NO-sGC is the axial ligand of the pentacoordinated 
reduced iron center of heme, which is required for NO activation of the enzyme. Thus, NO 
activates sGC by binding to the sixth position of the heme ring, which breaks the bond 
between the axial histidine and iron to form a 5-coordinated ring with NO in the fifth 
position as reported in [45].  
By using several experimental approaches as biochemical, pharmacological and molecular 
biology methods, we established that the first 20-s signal is a product of NO-sGC being 
sensitive to ODQ, as shown in Figure 2, which is translocated from cytoplasm to the inner 
face of the airway smooth muscle sarcolemma under muscarinic activation. 
In addition, there is a coupling mechanism between M2AChRs and NO-sGC involving a 
Go/Gi heterotrimeric proteins as previously demonstrated in [31]. Thus, in intact smooth 
muscle fragments and isolated plasma membranes from bovine tracheal smooth muscle, we 
showed that the heterodimer of NO-sGC involved in such translocation is the α1β1sGC. The 
experimental evidence using Western blotting with specific antibodies against all subunits 
of NO-sGC demonstrate that under muscarinic activation, the α1β1NO-sGC-heterodimer 
isoform is translocated from cytoplasm to plasma membranes of BTSM. These experimental 
data are shown in Figure 3.  
Since the capability of this α1β1-sGC to migrate to plasma membranes under muscarinic 
activation, a purification procedure and further identification of this α1β1-sGC heterodimer 
was also performed. Such NO-sGC translocation involves a M2AChR subtype as previously 
described in [31]. 
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Isolated BTSM strips were incubated in KRB at 37C in the presence and absence of muscarinic agonist Cch (1 x 10−5 M) 
for 70 sec in [36]. After each 10 s, the BTSM strips were removed and immediately frozen in liquid N2 and processed to 
prepare crude membranes fraction as described in [54]. In these membrane sediments, GC assays were performed in 
duplicate as described previously in [53]. Empty symbols represent GC assays performed by duplicate in the presence 
of 3 mM MnCl2, 0.2M GTP, 5 mM creatine phosphate, and 10 IU phospho-creatine kinase in 0.01% defatted BSA. Full 
symbols represent GC activity in the presence of 100 µM SNP. Basal (□), muscarinic agonist CC 1 x 10−5 M (○), basal 
plus SNP (▲), and CC+SNP (■). Each value is the mean of three different BTSM strips. 
Figure 2. Time-course of guanylyl cyclase activity in crude plasma membrane fractions isolated from 
BTSM strips under muscarinic agonist action. Taken from reference [31]. 
 
Figure 3. Western blotting of α1β1 NO-sGC-heterodimer from plasma membranes of BTSM under 
muscarinic activation as described in reference [31]. 
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Identification of α1/β1 sGC heterodimer in membrane fractions isolated from BTSM strips 
under muscarinic agonist exposure. Isolated BTSM were incubated in KRB at 37°C in the 
presence and absence of muscarinic agonist CC (1 x10−5 M) during 0, 20 s and 60 s. The 
samples were immediately frozen and pulverized with a mortar in liquid nitrogen, 
following the protocols described to isolate crude plasma membranes fraction as described 
in [31,54].  The final membranes sediments were electrophoresed in 12% PAGE-SDS, 
transferred to nitrocellulose membranes, and probed with specific antibodies against the α1, 
α2, (A) β1 and β2 (B) of NO-sGC subunits. The specific antibodies against α2 and β2 
produced negative results. This experiment was performed three times with similar results. 
Thus, we demonstrate that the first 20-s cGMP signal is a product of a novel signaling 
cascade involving M2AChR coupled to Go/i proteins, which facilitates the α1β1-sGC isoform 
migration from cytoplasm to the BTSM sarcolemma. These experimental evidences support 
a model for the M2AChR, Gi/o, and heterodimer of α1β1 of NO-sGC novel signal 
transducing cascade as illustrated in Figure 4. 
 
Figure 4. Model for the M2AChR, Gi/o, and heterodimer of α1β1 of NO-sGC novel signal transducing 
cascade in mammalian cells taken from reference [31]. 
Proposed model for a novel signal transducing cascade in mammalian cells involving three 
distinct molecular entities: M2AChR, Gi/o protein, and heterodimer of α1β1 of NO-sGC. (A) 
Basal condition: The hetero-dimer (α1β1NO-sGC) is located in the cytoplasm and the 
M2AChR and Gi/o proteins are macromolecules spanning and associated respectively with 
the plasma membrane bilayer. (B) Under muscarinic exposure, the agonist (Cch) binds at the 
extracellular domains of M2AChR causing the activation of M2AChR. This induces confor-
mational changes at the M2AChR cytoplasm domains stimulating a PTX-sensitive G protein 
(Gi/o), which may induce a migration and further activation of the α1β1 heterodimer NO-
sGC from cytoplasm to the plasma membrane resulting in a fast rise in cGMP production, 
which is related to the 20-s cGMP signal generated during the muscarinic activation of tra-
cheal smooth muscle cell. 
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In the other hand, the 60-s cGMP signal is a product of a Natriuretic Peptide Receptor 
Guanylylcyclase-B (NPR-GC-B), which was previously identified at TSM, using biochemical 
as reported in [38] and molecular biology approaches as described in [37]. The NPR-GC-B 
(GC-B) is a membrane-spanning homodimer form, which contains an extracellular ligand-
binding, trans-membrane, kinase homology, dimerization and carboxyl-terminal catalytic 
domains that was published in references [46,47]. NPR-GC-B, which is also called NPR-B or 
NPR2, is activated by CNP, which exists in 22 and 53 amino acid forms that are structurally 
similar to ANP and BNP as reported in references [48,49].  
Furthermore, this GC-B from TSM is a novel G-protein coupled guanylyl cyclase presents in 
isolated plasma membranes fractions from this smooth muscle subtype as described in [53]. 
This G-protein-coupled NPR-GG-B showed complex kinetics and regulation, which is sum-
marized in a proposed model as shown in Figure 5 as illustrated in reference [38]. This NPR-
B was activated by Natriuretic Peptides (CNP-53>CNP-22>ANP-28) at the Ligand Extracel-
lular Domain, stimulated by Gq-protein activators such as mastoparan, and inhibited by a 
chloride sensitive-Gi/o, interacting at the Juxtamembrane Domain. The Kinase Homology 
Domain was evaluated by the ATP inhibition of Mn2+-activated-NPR-B, which was partially 
reversed by mastoparan. The Catalytic Domain was studied by its kinetics of Mn2+/Mg2+ and 
GTP, and the catalytic effect with GTP analogs with modifications of the βγ phosphates and 
ribose moieties. Most NPR-B biochemical properties remained after detergent-solubilization 
but the mastoparan-activation and chloride-inhibition of NPR-B disappeared. This NPR-GC-
B is a highly regulated nano-machinery with domains acting at crosstalk points with other 
signal transducing cascades initiated by G-Protein Coupled Receptors (GPCR) and affected 
by intracellular ligands such as chloride, Mn2+, Mg2+, ATP and GTP. In addition, this model 
contains a novel GPRM domain, a G-protein-regulatory site, which was identified and char-
acterized as the binding domain for the G proteins subunits  as described in [38]. 
GC-B is abundantly expressed in brain, lung, bone, heart and ovary tissue as reported in 
[50]. GC-B contains three intramolecular disulfide bonds and is highly glycosylated on as-
paragine residues. Moreover, GC-B is highly phosphorylated and dephosphorylation is 
associated with receptor inhibition as described in [51]. ATP increases the enzymatic ac-
tivity of GC-B by reducing the Michaelis-Menten constant for GTP, an order of magnitude 
and this nucleotide seems to be essential for maximal activity as demonstrated in refer-
ence [52]. 
On the other hand, this Natriuretic Peptide Receptor Guanylylcyclase–B (NPR-GC-B), which 
has been previously identified as the predominant functional TSM membrane-bound GC 
subtype by using molecular biology in [37] and biochemical approaches as described in [38]. 
Nucleotide sequence of membrane-bound GC transcripts retrieved by RT-PCR correspond 
to the bovine GC-B isoform, indicating the predominance of this NPR-sensitive GC-B over 
GC-A and GC-C, which are also expressed in TSM in reference [37]. Both ANP and CNP 
stimulates the TSM membrane-bound GC activity in a concentration-dependent manner, but 
the CNP effect (10-8 to 10-5 M) was significantly higher than that exerted by ANP, whereas 
guanylin (a GC-C activator) showed no effect. Given that CNP specifically activates GC-B 
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receptors and that it activates GC-A receptors only marginally, the significant CNP effect on 
TSM cGMP production indicates that NPR-GC-B is the most abundantly expressed tracheal 
membrane-spanning GC isoform, further confirming the RT-PCR results in [37]. 
 
Figure 5. Proposed model of the  G-protein coupled NPR-GC-B as illustrated in reference [38]. 
This NPR-GC-B is regulated in an opposite way by two MAChRs signaling cascades, acting 
the M2AChR as an inhibitor and the M3AChRs as an activator of this NPR-GC-B as 
mentioned in [55]. 
This novel signal transducing system is illustrated as a model in Figure 6.  The relevant 
feature of these two opposite signal cascades that regulate this NPR-GC-B is the coupling of 
two MAChRs and distinctive G proteins. Thus, this activation system coupled a M3AChR to 
a Gq16 being stimulated by mastoparans (tetradecapeptides from wasp venoms), whereas, 
on the inhibitor cascade of NPR-GC-B, via M2AChR coupled to a Go/Gi protein has been 
previously described in references [35,38,56].   
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Figure 6. Schematic model of signal cascade involving m3AChR/Gq16/NPR-GC-B at BTSM in [56]. 
A model for coupling M3AChR, via Gqα16ßγ to activate NPR-GC-B in plasma membranes 
from BTSM. This model is composed of three separate and different molecular entities, 
M3AChR, a GPCR seven transmembrane receptor, a heterotrimeric G protein and 
homodimeric NPR-GC (cGMP producing enzyme) as the effector. The drawings do not take 
into account the actual structural biology (molecular mass) of these entities; it is a scheme to 
suggest the flow of information in this novel signal transducing cascade, which is indicated 
by the dashed lines. Thus, a muscarinic agonist (ACh) binds at extracellullar domains of 
M3AChR inducing conformational changes at the cytoplasmic i3M3AChR domain, which 
stimulates the Gqα16ßγ, to release its active subunits that interact with NPR-GC. Mastoparan 
and its active analogues may act at the interactions between i3M3AChR domain and the 
Gqα16ßγ protein as indicated in the scheme. 
Mastoparans are tetradecapeptides isolated from wasp venom as reported in [57,58] and 
they are well known as heterotrimeric G-protein activators as described in [59,60]. Moreo-
ver, mastoparan is able to activate the NPR-GC-B associated with plasma membranes frac-
tions from TSM in [56]. Following these results, we evaluate the effect of these peptides on 
TSM contraction. It was found that mastoparan and analogs were able to inhibit in a selec-
tive manner the BTSM contraction induced by muscarinic agonist as carbachol (CC) as 
shown in Figure 7. Thus, our original findings indicated that mastoparans in the nM range 
decreased the contractile maximal responses induced by CC without changing its EC50. One 
explanation for the decrement on the contractile maximal responses by mastoparans may be 
related to the ability of these tetradecapeptides to disturb the function and the contractile 
machinery of the BTSM type through cytotoxic mechanisms, which have been described in 
other biological models, specifically in the µM concentration range as described in [61,62]. 
This assumption is not supported by our results on the effects of classic TSM spasmogens as 
5-HT in as described in reference [63], which produced potent contractions even in the 
presence of mastoparan (nM) as shown in Figure 8. These findings can be explained since 
this bioactive amine has been claimed to exert their physiological effects on TSM through 
Current Basic and Pathological Approaches to  
the Function of Muscle Cells and Tissues – From Molecules to Humans 
 
122 
specific GPCRs. These receptors are the 5-HT2A, which induced activation of the Gq/11 
protein and its downstream effector phospholipase C (PLC) leading to intracellular 
phosphatidylinositol turnover and Ca2+mobilization as reported in [64]. These Gq/11 
proteins are mastoparan-insensitive ones. The latter facts can explain the mastoparan-
insensitivity of the serotoninergic transducing cascades at TSM. Furthermore, our results 
demonstrated that mastoparan inhibits selectively the muscarinic activation without altering 
other spasmogens transducing cascades at TSM. 
 
The BTSM strips contractile activity was measured using Procedure 1 as previously described in [36]. Carbachol 
cumulative responses using concentrations from 1x10–9 M to 1x10–4 M were measured in recording period until 3 min. 
Mastoparan was pre-incubated for 10 min before the muscarinic agonist (carbachol) addition. Experimental conditions: 
(■) Control, (▲) 0.5nM (▼) 1 nM (○) 5 nM (□) 10 nM (●) 50nM.  The maximal contractile activity was considered as 
100% (3.2 ± 0.2 g) and this value was used to estimate other contractile responses. Each value is the mean ± SEM of 
three different tracheas assayed in duplicate.  
Figure 7. Carbachol cumulative concentration curves responses from BTSM, pre-treated with masto-
paran. 
From the data above mentioned, mastoparan can affect specifically the signal cascades 
associated with the muscarinic activation at TSM sarcolemma, which are initiated with a 
mAChRs coupled to heterotrimeric G-proteins in reference [65].  These results indicate that 
the most like candidates implicated in mastoparan effects are the heterotrimeric G-proteins 
coupled to these mAChRs. G protein involvement on the mastoparan inhibition on TSM 
muscarinic activation is supported by the ability of this G-protein activator to alter the 
generation of the two GMPc signals at 20-s and 60-s as previously described in [36]. 
Mastoparan (50 nM) induced a potent inhibition of these cGMP signals, as shown in 
Figure 8. After mastoparan pre-incubation, the kinetics of cGMP intracellular levels at 
TSM was evaluated following the muscarinic agonist exposure. Interestingly, the first 
cGMP signal (20-s) decreased in more than 60% and the second signal peak (60-s) 
completely vanished. 
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The disappearance of the second signal of cGMP (60-s) correlates well with a significant 
reduction on the contractile maximal responses as here described in Figure 7. This 60-s 
cGMP signal is a product of NPR-GC-B as above mentioned in references [35,54,55]. 
Recently, we further recognized that muscarinic agonist and mastoparan activations of 
NPR-GC-B in isolated BTSM plasma membranes fraction involve this mastoparan-sensitive-
Gq16 protein in [54]. Thus, the pre-exposure of TSM strips to mastoparan stimulated the Gq16 
protein, disrupting this signal cascade inducing the failure of this muscarinic-dependent TSM 
contraction. However, the serotoninergic-dependent TSM contraction remained functionally 
active indicating that the smooth muscle machinery remains fully active. 
 
BTSM fragments were stabilized for 1 h using a procedure described previously in [36]. Later, mastoparan (50 nM) was 
added for 10 min, followed by carbachol (CC) (1x 10-4 M), serotonin or 5-hydroxytryptamine (5-HT) (1x 10-4 M) and 
Atropine (AT) (1x10-4M) was added. Values between parentheses are the final concentration of drugs in the incubation 
media. This trace is representative of 3 experiments performed with 3 different tracheas fragments. 
Figure 8. Serotonin (5HT) induced contractile responses in mastoparan-treated BTSM strips. 
Until now, the BTSM muscarinic activation is unique biological system that involves two 
cGMP signals as second messengers in references [35,36]. In addition, this activation is a 
highly regulated biological process, which starts with M2/M3AChRs coupled to two different 
heterotrimeric G proteins, leading to a fine time regulation and stimulation of two distinc-
tive guanylyl cyclases that accomplish the generation of these two (20-s and 60-s) cGMP 
signal peaks. 
Based in our results, it can be postulated that the first cGMP signal (20-s) is a product of the 
activation of one M2AChR subtype coupled to a PTX-sensitive-Gi/o protein that leads to the 
translocation and further activation of the heterodimer α1β1 NO-sGC isoform, anchored to 
plasma membrane. Recently, it has been suggested that a plasma membrane-bound GC, 
may provide a localized pool of cGMP in [68], which seems to be in a similar trend suggest-
ed by our work.  The second signal peak is a product of a the activation of M3AChR coupled 
to the stimulation of mastoparan-sensitive Gq16 as reported in reference [54] to turn on a 
transmembrane-homodimer as NPR-GC-B as described in [35,55]. 
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BTSM strips were assayed using following Procedure 2 as described in [36]. Pre-incubation for 10 min with 
mastoparan (□) (50nM) was performed. Control experiments (▲) without drugs were run simultaneously under the 
same conditions. Each value is the mean X ± SEM of four different tracheas, and the cGMP determinations were carried 
out in triplicate as described in references [36,53]. Statistically significant difference between the Control with respect 
to mastoparan as indicated with asterisk (*p<0.05). 
Figure 9. Mastoparan effect on cGMP signal peaks induced by muscarinic agonist (carbachol) in TSM. 
Thus, a dysfunction of these M2/M3AChR signal transducing cascades has been implied in 
the pathophysiological mechanisms of bronchial asthma as mentioned in references [1,3,4] 
and Chronic Obstructive Pulmonary Disease (COPD) in [3]. In this sense, we attempted to 
evaluate these novel signal transducing cascades involving guanylyl cyclase activities above 
discussed, in an experimental asthma model in rats as described in reference [70]. In addi-
tion, it has been claimed that excessive NO production that occurs in asthma induces a 
down-regulation of NO-sGC as reported in [69].  
Following these rationale, we used cultured Airway Smooth Muscle Cells (ASMC) from 
Control and an experimental asthma model (Ovoalbumin exposed rats or OVA-ASMC), 
which were sensitized to Ovoalbumin using a procedure described in [70,71]. In these 
ASMC, we evaluate the cGMP production by NPR-GC-B stimulated by muscarinic agonists, 
mastoparans, natriuretic peptides (ANP, CNP) and for NO-sGC, a classic NO donor as So-
diun NitroPrusside (SNP) and a selective inhibitor for the NO-sGC as 1H-[1, 2,4] Oxadia-
zolo[ 4,3-a]quinoxalin-1-one (ODQ) were used. 
All ASMC exposed to a NO-donor compound as SNP and muscarinic agonist as CC in-
creased cGMP intracellular levels, which were inhibited by ODQ, suggesting that NO-sGC 
is present and this activity is partially responsible for cGMP production in these ASMC. 
However, OVA-ASMC showed low basal cGMP production compared to CONTROL ASMC 
in reference [71] as shown in Figure 10 possibly due to substantial reduced NO-sGC expres-
sion reflected in decrease the steady state levels of NO-sGC subunit mRNAs and protein 
level expression, as described in intact lung tissue from OVA-sensitized mice described 
elsewhere in reference [69].  
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Cyclic GMP (cGMP) production in airway smooth muscle cells (ASMC) from CONTROL and OVA- sensitized rats. 
The ASMC were incubated for 15 min in the presence of IBMX as described in reference [70]. Cyclic GMP production 
was determined in the presence of Cch, SNP and ODQ as described in Methods. The cGMP produced was estimated 
by duplicate using a radioimmunoassay kit from Amersham as described in [70]. Each value is the mean + of   5 
different experiments. In both groups, the amounts of cell cultures plates were obtained for a pool of 5 rats. The 
stadistical significance between CONTROL vs OVA was established as p<0.05 (*) and p< 0.001 (**). 
Figure 10. The effect of NO-sGC activators and inhibitors on total GC activity from Control and OVA 
ASMC. Taken from reference [70]. 
Trying to understand the role of the NPR-GC-B in the ASMC, we studied the effect of sever-
al activators of this NPR-GC such as natriuretic peptides (ANP and CNP) and mastoparans  
as previously described in BTSM in references [37,38,71]. Thus, ASMC from Control and 
OVA-exposed rats were cultured and exposed to these NPR-GC-B activators. Thus, in Fig-
ure 11, the total GC activity at OVA-ASMC was stimulated by CNP, ANP and muscarinic 
agonist (Cch) indicating that NPR-GC-B was present in Control ASMC, which are similar 
results described in intact BTSM strips and isolated plasma membranes from BTSM in refer-
ences [37,38,53,55]. In addition, the OVA-ASMC showed a more significant stimulation by 
these NPR-GC activators. Interestinly, the combination of CC plus ANP and CNP increased 
in more than 6 times the GC activity. As expected, mastoparan, an activator of NPR-GC-B, 
via Gq16 dramatically increased in 5 times, the GC activity as reported in [72]. These data 
showed for the first time that there is an hyperstimulation of M3AChR/Gq16/NPR-GC-B 
cascade in ASMC from a experimental asthma model.  
Taking together all these results indicate that the ASMC from OVA-sensitized rats express a 
reduced NO-sGC activity and an increased in the NPR-GC-B activity. This imbalance be-
tween these two guanylyl cyclases can contribute to airway hyperreactivity and might be 
implicated in the hyperplastic smooth muscle responses and remodeling present in asthma. 
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All these previous experimental data unravels some of complex molecular mechanisms 
associated with the muscarinic activation of ASM. This muscarinic activation is the most 
physiological, pathophysiological and pharmacological relevant mechanisms because Ach is 
the neurotransmitter-linked stimulation of ASM in asthma and COPD. Thus, this works 
opens new trends for the pathophysiological and pharmacological mechanisms, which may 
lead to new therapeutic approaches for the treatment of these chronic respiratory diseases, 
such as asthma and COPD, in which, the ASM is involved. 
 
The effect of NPR-GC activators on total GC activity in Control and OVA ASMC. The OVA and Control ASMC were 
incubated for 15 min in the presence of 100 µM IBMX (non-selective PDEs inhibitor). Cyclic GMP production was 
determined in the presence of Cch (1x10-5 M), Mastoparan (1x10-7M), CNP (1x10-7M) and ANP (1x10-7M). The reaction 
was stopped by removing the medium immediately and freezing with liquid N2 was later 500 µl of TCA 6%, mixed 
vigorously and centrifuged for 1,500 g x 15 min. The acid extract was treated 2 times with ether saturated with water 
and the water phase was then lyophilized and suspended in 0.150 ml of water. The cGMP produced  by these cells 
were determined using a radioimmunoassay kit as previously described in reference [70]. 
Figure 11. The effect of NPR-GC activators on total GC activity in Control and OVA ASMC. 
3. Conclusion 
In this review, we exposed the recent experimental evidences, in relation to the generation 
of cGMP, on the muscarinic activation of ASM, which is the essential element in the bron-
choconstriction presents in asthma.  
Moreover, this muscarinic activation seems to be involved in the remodelling and functional 
changes of ASM described in asthma and COPD as described in references [1-6,73]. We 
discussed the existence of two cGMP signals, at 20-s and 60-s in [36], which are products of 
two distinctive guanylyl cyclases, the NO-sensitive soluble guanylyl cyclases (NO-sGC) and 
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Natriuretic Peptide Receptor Guanylyl Cyclase-B (NPR-GC-B). The 20-s cGMP signal is 
linked to the activation of a M2AChR coupled to Go/Gi proteins inducing a massive and 
transient α1β1-NO-sGC translocation from cytoplasm to plasma membranes of ASM as 
reported in [31].  
The 60-s cGMP signal is associated with a NPR-GC-B in [37], a novel G-protein coupled 
NPR-GC-B as described in references [38,53,55], which is nano-machine regulated by 
GPCR and also modulated, in an opposite way, by an activator M3AChRs coupled to Gq16 
to activate NPR-GC-B (M3AChR/Gq16/NPR-GC-B cascade) that is stimulated by masto-
paran as reported in [56] and an inhibitor M2AChR signal cascade that was partially char-
acterized.  
Mastoparan inhibited in a selective manner the muscarinic-dependent ASM contraction and 
affected the two cGMP signals. The ASM muscarinic activation is unique biological system 
involving two cGMP signals and a dysfunction of these M2/M3AChR cascades has been 
implied in asthma and COPD as published in references [1-6].  
We used another mammalian model as ASM from rats, which are more prone to develop 
experimental asthma using Ovoalbumin leading to the OVA-sensitized rats model as de-
scribed in [70,71]. In isolated and cultured Airway Smooth Muscle Cells (ASMC) from Con-
trol and OVA, we evaluated the cGMP production in these ASM cultured cells. All ASMC 
showed cGMP increments by  a classic NO donor as SNP being ODQ-sensitive, indicating 
that NO-sGC is present, but OVA-ASMC showed low basal cGMP production compared to 
Control ASMC described in [71], which confirmed the molecular biology results reported 
elsewhere in reference [69]. Moreover, NPR-GC-B is present in Control ASMC but OVA 
ASMC displayed an hyperstimulation of M3AChR/Gq16/NPR-GC-B cascade, which is an 
original experimental findings as reported in [72].  
These results indicate that the OVA-ASMC express a reduced NO-sGC and increased NPR-
GC-B activities. This imbalance between these two GCs can contribute to airway hyperreac-
tivity and might be implicated in the abnormal ASM responses present in asthma and 
COPD. 
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